Ascendis Pharma A/S (ASND)

followers · Follow

Sector:	HEALTH CARE
Industry:	PHARMACEUTICALS
SIC:	PHARMACEUTICAL PREPARATIONS
CEO:	Jan M. Mikkelsen
Employees:	640
Web site:	ascendispharma.com
TUBORG BOULEVARD 12, HELLERUP, G7, DK-2900 45 70 22 22 44

	All 13F Filers	Prior	Change	Hedge Funds ¹	Prior	Change

SKYTROFA for treating patients with growth hormone deficiency (GHD) Ascendis Pharma A/S focuses on developing therapeutics for unmet medical needs. It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD. TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia.

Please log in first to see chart

Ascendis Pharma A/S YCharts
Yahoo! Finance	finviz
SEC Web Site	SEC DEF 14A Filings

Shareholders (13F, 13D/G)

Current Mutual Fund/ETF Holders

Active 13D/G Filings

SEC Filings

Insiders

Short Positions

Congress

Proposed Sales

Comments and Updates

To Excel | To CSV | To TSV

Investor	History	Shares Held or Principal Amt	Market Value	% of Portfolio	Previous % of Portfolio	Rank	Change in Shares	% Change in Shares	% Ownership	Qtr 1st Owned	Est. Avg Price	Source	Source Date	Date Reported
No data available